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Abstract 
Introduction: The incidence of HIV/AIDS is increasing worldwide and in the Middle East. In this study, we analyzed the use of antiretroviral 
therapy (ART), the patterns of CD4 and viral load (VL), and stage of presentation. 
Methodology: Laboratory variables, ART use, and CD4 count were obtained and analyzed retrospectively. 
Results: A total of 997 cases from eight HIV/AIDS care providers were included. Of the total cases, 274 (28.3%) had a CD4 count of < 200 
cells/mm3, and 413 (42.3%) had a viral load of > 5 log10. Of the total cases, 50% were on highly active antiretroviral therapy (HAART), and 
the majority of cases were asymptomatic (70%). Of those patients on ART, 247 (39.5%) took tenofovir/emtricitabine combined with either 
efavirenz (147; 14.7%) or lopinavir/ritonavir (100; 10%), and 158 (15.8%) were on lamivudine and zidovudine with either efavirenz (32; 
3.2%) or lopinavir/ritonavir (126; 12.6%). Other combinations were used in 70 (7%) patients. The mean (± standard deviation) of baseline 
CD4 and viral load were 401 cells/mm3 (322 cells/mm3) and 4.6 log1010 (1.3 log10), respectively. At diagnosis, 72% of patients were 
asymptomatic; 50% had AIDS and 20% had CD4 count < 350. 
Conclusions: ART use was in line with international guidelines, but the number of patients receiving ART was lower than expected. Large 
proportions of cases presented late with AIDS at diagnosis or had CD4 < 350. Further data is needed to evaluate the medical care of patients 
with HIV/AIDS in the Kingdom of Saudi Arabia. 
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Introduction 
Following the emergence of the HIV/AIDS 
epidemic in the early 1980s, there was a response to 
early cases of HIV/AIDS in the Kingdom of Saudi 
Arabia (KSA). The first cases were reported in the 
KSA around 1984, following which, surveillance of 
HIV commenced. However, formal concerted 
activities related to HIV/AIDS were only launched 
after the inception of the National AIDS Program 
(NAP) as a directorate of the Public Health branch of 
the Ministry of Health in 1996 [1]. 
Reliable monitoring of this program remains a 
challenge due to the lack of dependable data collection 
systems across a wide range of public and private 
sector providers of HIV/AIDS care, and due to hard-
to-reach risk groups in a country as vast as the KSA. 
Nonetheless, in the last decade, returns of prevalence 
and risk behavior data to the World Health 
Organization (WHO)’s UNAIDS program has been 
regular despite the widely held belief that these reports 
underestimate the real burden of HIV/AIDS in the 
KSA. The most recent UNAIDS country progress 
report published in 2014 revealed that the incidence of 
HIV among Saudis has increased by 44% in 2013 
compared to 2012 [2]. However, the overall 
prevalence of HIV/AIDS is consistently low (< 0.2%). 
The prevalence of HIV seems to be heterogeneous 
between the populations of the same country and 
across countries in the Middle East and North Africa 
(MENA) WHO region. The overall incidence and 
prevalence of HIV/AIDS is widely thought to be 
understating the real burden of disease due to 
incomplete surveys and the widespread stigmatization 
in this region [3-5]. In addition, clinic-based cohort 
studies have suggested that patients are presenting late 
with AIDS. It is hoped that with better surveys, and 
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more programmatic work to reduce the stigma 
associated with HIV/AIDS, the epidemic in this region 
will be better understood and reduced [6,7]. 
There is scarce published data on the use of 
antiretroviral therapy in the KSA. Presently, there are 
no agreed-upon national treatment guidelines; the 
international guidelines are presumably being used, 
albeit on an ad hoc basis. Therefore, clinical practice 
is likely to be diverse due to the lack of agreed-upon 
national or local treatment standards [7]. 
According to the 2013 World Development 
Report, the KSA is considered a high-income country. 
By law, ART should be available free of charge. 
However, options for treating affected patients are still 
limited. Viral resistance testing is not available to most 
treating centers, and co-receptor and HLA-B 5701 
screening are not accessible to most providers. 
Monitoring of response to ART is important to 
evaluate the medical care of people living with 
HIV/AIDS, especially in light of reports that mortality 
associated with HIV/AIDS is high in the KSA and 
elsewhere in the MENA region. In the era of ART, in 
both resource-rich and resource-poor countries alike, 
late presentation and poor access to services, among 
other factors, are associated with high mortality [8-
10]. In this study from the KSA, we describe the 
pattern of ART use, baseline CD4 and viral load, and 
disease stage at diagnosis. We aimed to determine the 
ART that patients received and whether the therapy 
was in line with international treatment guidelines, to 
determine the baseline CD4 and viral load (VL), and 
to determine whether late presentation was an issue. 
We anticipated this study would serve as a baseline to 
measure future progress, a first step to fill in many 
gaps in the information about medical care of people 
living of HIV/AIDS in the KSA. Thus, we hope, 
through further future similar work in the area of HIV 
medical care, to inform providers to standardize care, 
reduce morbidity and mortality, monitor and reduce 
resistance to ART, and ultimately improve the quality 
of life for those living with HIV/AIDS [11-13]. 
 
Methodology 
Data on new HIV patients reported in the KSA 
from 2001–2013, as reported to the HIV surveillance 
system according to the Ministry of Health 
requirement, were analyzed, along with  ART used, 
CD4 count, VL, and the Centers for Disease Control 
and Prevention (CDC) stage at diagnosis.    
The data was stored in a Microsoft Excel sheet, 
and then transferred to SPSS (version 21) software for 
analysis. 
 
Results 
Data from 977 patients living with HIV were 
available from eight providers in all regions of the 
KSA. The regions included Western, 52%; Southern, 
23%; Eastern 24%; and others, 1% (Figure 1). 
Of the total cases, the majority were asymptomatic 
(70%), 274 (28.3%) had a CD4 count of < 200 
cells/mm
3
, and 413 (42.3%) had viral load of > 5 log10 
(Table 1). Fifty percent of cases had a CD4 count of < 
350 cells/mm
3
. The mean nadir CD4 and baseline VL 
were 401 cells/mm
3
 (± 322) and 4.6 log10 copies/mL 
(± 1.3). Of the total cases, 50% were on highly active 
antiretroviral therapy (HAART), and 
efavirenz/tenofovir/emtricitabine was the most 
frequently used combination (14.7%), followed by 
lopinavir/ritonavir and lamivudine/zuduvidine (12.6%) 
Figure 1. Geographic distribution of the included patients 
Table 1. Cross-tabulation of CD4 count and viral load categories 
 
CD4 level 
Total 
> 200 < 200 
Viral load category 
< 100,000 381 (39%) 183 (18.7%) 564 (57.7%) 
> 100,000 227 (23.3%) 186 (19%) 413 (42.3%) 
Total 703 (72%) 274 (28%) 977 (100%) 
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(Table 2). A total of 3.2% of patients received 
efavirenz/lamivudine/ziduvidine and 
lopinavir/ritonavir, and 10% received 
tenofovir/emtricitabine. 
Table 3 displays the CDC stage and test setting of 
the participants at the time of diagnosis. The largest 
proportions were those in CDC stages A1–3, which 
included high-risk asymptomatic patients such as 
prisoners, patients who inject drugs (PWID), and 
patients who were contacts of known cases. 
The risk categories by regions revealed that the 
Western region followed by the Eastern and Southern 
regions had the highest proportion of people living 
with HIV/AIDS, at 54%, 24%, and 23%, respectively. 
In addition, results showed that the commonest mode 
of transmission was heterosexual, followed by 
unknown mode of transmission, except in the Eastern 
region, where PWID was the second-most common 
(Figure 2). 
 
Discussion 
Our results suggested that 50% of the patients 
were taking ART. Also, the great majority were taking 
the recommended first-line or alternative therapies per 
international authoritative guidelines [14-18]. 
Consistent with previously published reports, most 
of the patients lived in the Western region of the KSA, 
and they were asymptomatic at diagnosis [15-18]. The 
majority of cases were asymptomatic (70%), 
indicating success of the screening program to identify 
high-risk behavior and test those who might be at high 
risk of HIV infection. 
To our knowledge, this is the first time that the use 
of ART has been described in HIV/AIDS patients in 
the KSA, and there is no similar data with which to 
compare our results. In our sample, 80% of patients 
were diagnosed between 2006 and 2013, a period in 
which all authoritative international HIV treatment 
guidelines at least recommended the use of ART in 
patients whose CD4 count was ≤ 350, especially since 
Table 2. Frequency of antiretroviral therapy used 
Antiretroviral (ARV) medication Percent of PLHIV on ARV at time of study 
Efavirenz/truvada 147 (14.7%) 
Kaletra/truvada 100 (10.0%) 
Efavirenz/combivir 32 (3.2%) 
Kaletra/combivir 126 (12.6%) 
Others 70 (7.0%) 
Not on ART 522 (52.4%) 
Total 997 (100%) 
PLHIV= People living with HIV 
 
 
Table 1. HIV status and CDC disease stage 
 
Reason for HIV test 
Screening High risk Symptomatic 
% % % 
A1 10.1 16.5 1.6 
A2 15.5 14.3 1.5 
A3 4.9 5.3 1.7 
B1 0.0 0.7 1.0 
B2 1.3 2.7 2.8 
B3 0.8 1.4 2.7 
C1 0.1 0.4 0.2 
C2 0.2 0.6 1.8 
C3 1.5 2.3 7.8 
 
Figure 2. Mode of transmission by region 
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2011 [16-19]. 
The therapeutic combinations used in ART 
reflected international treatment guidelines, with the 
exception of first-line protease inhibitors (PIs) [14-18]; 
lopinavir/ritonavir are not considered first-line drugs 
[14]. 
The mean CD4 counts and VLs reflected a mixed 
patient population, ranging from routine premarital 
screening to sick patients in hospitals, as was 
described in a previous study [7]. 
The Central region – mainly the city of Riyadh – is 
underrepresented in our sample, as data could only be 
obtained from providers under the Ministry of Health, 
and non-Ministry of Health providers dominate 
HIV/AIDS care in Riyadh. Therefore, we advise 
caution in generalizing our result in this region. 
 
Conclusions 
Our results showed that while the ART drugs in 
use were generally in line with international 
guidelines, the proportion of patients taking them was 
lower than anticipated, and the number of patients who 
presented late was considerably higher than desired. 
Therefore, we recommend that ART and HIV testing 
should be offered more actively. Further and better 
surveillance data that include new variables, such as 
CD4, are needed to monitor drug treatment of 
HIV/AIDS. This will expand on our findings, and 
provide clearer insight into the drug therapy of 
HIV/AIDS in the KSA. Future studies should also 
evaluate the differences in outcome and survival 
between those who received ART and those who did 
not. 
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